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S-1, a novel ora川uoropyrimidine, has increasingly been used for the treatment of many types of human
cancerincluding gastrointestinalcarcinomas, breast, lung, head & neck etcl　0Xaliplatin is a third一generation
platinum compound, has been used for the treatment of gastrointestinalmalignancies･ The purpose of the pres-
ent study is to investigate whether S- 1 (prodrug of 5-FU) and Oxaliplatin combinationchemotherapy was euec-
tive to human ovarian cancer. SHIN-3, human ovarian cancer cell line was usedinthis study. Nudemice in-
jecting tumor cells in the abdominal cavity were treat,edwith 10 mgn'g Sll, and 3.35 mgn'g, 1.67 mがkg
Oxaliplatin or both. Tumor weight on the days of 21 was the treatments'endpoint･ The results showed that
while Sll or Oxaliplatin were slightly effective as slngle agents in tumor weight, the combined treatment was
highly effective. (Control ; 1.47±0.18 g, S-1 ; 0.91±0･40 g, 0Ⅹaliplatin ; 0･86±0･48g, S-1+0Ⅹaliplatin ;
0.06±0.05 g.) Wealso examined the anticancer efBcacy using biomarker CA-125･ But there were few euects
of combining treatment, whereas in vivo tumor weight experiment demonstrated higheffectiveness･ (Con-
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trol ; 28.55±08.56U/ml, S-1 ; 2.83±4.28 U/ml, 0Ⅹaliplatin ; 4.87±4.49 U/ml, S-1+0Ⅹaliplatin ; 3.70±1.74 U/
ml.) To detemine whether S-1 and Oxaliplatin combinationchemotherapy is euective on SHN-3 humanovar-
ian cancer cells, MTT assay were used. The result shows that combination therapy were slightly effective than
single agents therapy. (Control ; 1±0.12, 5-FU ; 0.71±0.06 , 0Ⅹaliplatin ; 0.64±0.16, 5-FU+0Ⅹaliplatin ;











































































与), S-1 (10mgn(g (5-FU相当))単独群,
L-OHP (3.35m〆kg)単独群, L-OHP (1.67mg/
kg)単独群, S-1 (10 mgn(g(5-FU相当)) + (3.35 mg/






























うに当たり, Immunospec Corporation (U.S.)製
のCA-125EuSAKit (96tests)を使用し,手順は
付属のプロトコルに準じて行った｡
2-5 in vitrD系による3- (4,5-dmethylthiazo1-2-
yl) 12,5diphenyltetra20lium brmide (MTT)














































S-1 (10mgn(g5-FU相当) 0.91±0.40g, L-OHP
(3.35 mgnig) 0.31±0.27g. L-OHP (1.67 mgn(g)
0.86±0.48g, S-1 (10mかkg51FU相当)+ L-OHP
(3.35 mgn(g) 0.01±0.02 g, S-1 (10 mgnig 5-FU


















L-OHP (3.35mgn(g) (d) L-OHP (1.67mg/
kg) (e) S-1 (10mかkg5-FU相当)+L-OHP
(3.35mgn(g) (i) S-1 (10mgn(g5-FU相当)十
LOHP (1.67 mdkg)
BarはSDを示す
- 【 l l ? 
【 l 




(a) Control (b) S-1 (10mdkg5-FU相当) (C) L-OHP (3.35mgn(g) (d) L-OHP (1.67mgn(g) (e)

















tro1 28.55±08.56U/ml, S-1 (10 mgn(g 5-FU相当)
02.83±4.28 U/hd, L-0Ⅰ廿(3.35 mが(蛋) 4.56±0.55 U/
ml, L-OHP (1.67mgn(g) 4.87±4.49U/ml, Sl1 (10
men(g 5-FU相当) +L-OHP (3.35mgnig) 0.47±
2.llU/ml, S-1 (10mgn(g5lFU相当)+ L-OHP

















の相対値は5-FU (800pM) 0.71±0.06, L-OHP











L-OHP (3.35mgn(g) (d) L-OHP (1.67md
kg) (e) S-1 (10mgn(g5-FU相当)+L-OHP















(a) Control (b) 5-FU (800uM) (C) L-OHP
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